Show simple item record

dc.contributor.authorPro, B
dc.contributor.authorAdvani, R
dc.contributor.authorBrice, P
dc.contributor.authorBartlett, N
dc.contributor.authorRosenblatt, J
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorMatous, J
dc.contributor.authorRamchandren, R
dc.contributor.authorFanale, M
dc.contributor.authorConnors, J
dc.contributor.authorFenton, K
dc.contributor.authorHuebner, D
dc.contributor.authorPinelli, J
dc.contributor.authorKennedy, D
dc.contributor.authorShustov, A
dc.date.accessioned2017-11-23T21:05:09Z
dc.date.available2017-11-23T21:05:09Z
dc.date.issued2017-10-03
dc.identifier.citationFive-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. 2017, Blooden
dc.identifier.issn1528-0020
dc.identifier.pmid28974506
dc.identifier.doi10.1182/blood-2017-05-780049
dc.identifier.urihttp://hdl.handle.net/10541/620690
dc.descriptionLymphoma Research Teamen
dc.description.abstractThis pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (N=58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in-remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16, 8 patients received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, demonstrating a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.
dc.language.isoenen
dc.rightsArchived with thanks to Blooden
dc.titleFive-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.en
dc.typeArticleen
dc.contributor.departmentRobert H. Lurie Comprehensive Cancer Center, Chicago, IL, United Statesen
dc.identifier.journalBlooden
html.description.abstractThis pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (N=58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in-remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16, 8 patients received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, demonstrating a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.


This item appears in the following Collection(s)

Show simple item record